Amarin | AMRN - Pre Tax Profit


Amarin reported $-852K in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amarin USD -852K 7.26M Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
DBV Technologies USD -33.16M 8.6M Sep/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 3.84B 802M Mar/2026